Riggert, Joachim

[["dc.bibliographiccitation.firstpage","1127"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1133"],["dc.bibliographiccitation.volume","96"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:22:22Z"],["dc.date.available","2018-11-07T10:22:22Z"],["dc.date.issued","2017"],["dc.description.abstract","Graft-versus-host disease (GvHD) still belongs to the major challenges after allogeneic hematopoietic stem cell transplantation (HSCT). Immune-suppressive therapy against GvHD is a double-edged sword due to risk of infections and relapse. The ability to adapt prophylactic treatment according to the probability of severe GvHD would be an essential advantage for the patients. We analyzed different biomarkers for their potential to predict the development of GvHD in 28 patients who underwent allogeneic HSCT. Blood was taken once directly after hematopoietic engraftment. In this study, patients were monitored for 12 months after HSCT for the occurrence of acute GvHD or acute/chronic GvHD overlap syndrome. Soluble IL-2 receptor and CD4/CD8 T cell ratio were independently associated with the occurrence of GvHD in the observation period. However, the largest area under the receiver operating characteristic curve with 0.90 was observed when a 5-parameter biomarker score based on CD4(+) T cells, CD8(+) T cells, CD19(-) CD21(+) precursor B cells, CD4/CD8 T cell ratio, and soluble IL-2 receptor was used to predict GvHD. In addition, CD8(+) T cell levels above 2.3% of all mononuclear cells after engraftment may predict relapse-free survival at least for 12 months. In summary, we found a new biomarker panel for prediction of GvHD which is featured by established laboratory assays and high statistical significance. In order to introduce the biomarker panel into routine clinical protocols, we suggest performing a larger multi-center study."],["dc.identifier.doi","10.1007/s00277-017-2999-5"],["dc.identifier.isi","000403078900008"],["dc.identifier.pmid","28447161"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42255"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1432-0584"],["dc.relation.issn","0939-5555"],["dc.title","Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","109"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Clinical Apheresis"],["dc.bibliographiccitation.lastpage","113"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Humpe, Andreas"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Koch, S."],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Munzel, U."],["dc.contributor.author","Kohler, M."],["dc.date.accessioned","2018-11-07T09:34:58Z"],["dc.date.available","2018-11-07T09:34:58Z"],["dc.date.issued","2001"],["dc.description.abstract","Some data exist on the influence of leukapheresis volume on the number of harvested peripheral blood hematopoietic progenitor cells (HPC), but less is known about the influence on the composition of HPC. We therefore performed a prospective, randomized crossover trial to evaluate the effect of large-volume (LVL) vs. normal-volume leukapheresis (NVL) on subpopulations of CD34(+) cells in the harvest product of 15 patients with breast cancer and 8 patients with non-Hodgkin's lymphoma. Patients were randomly assigned to start either with an LVL on day 1 followed by an NVL on day 2 or vice versa. The number of HPC; the extraction efficiency defined as difference between yield in the harvest and decrease in peripheral blood, and the relative proportion as well as the absolute numbers of CD34(+) cells coexpressing CD38, CD90, HLA-DR, CD117, CD7, CD19, CD41, or CD33 were evaluated. There was no significant difference with regard to the percentages of the subsets on comparison of LVL to NVL procedures. Only the absolute median number of CD34(+)HLA-DR- cells was significantly (P=0.02) higher in LVL harvests compared with the corresponding NVL components; which can be explained on the basis of the higher yield and the higher extraction efficiency in LVL compared with NVL. LVL results in a higher yield of CD34(+) cells and leads to an intra-apheresis recruitment of HPC but the relative composition of the harvested CD34(+) cells is not changed significantly. In addition, the amount of early, HLA-DR-, hematopoietic HPC seems to be increased by an LVL. (C) 2001 Wiley-Liss, Inc."],["dc.identifier.isi","000171650400001"],["dc.identifier.pmid","11746535"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32289"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-liss"],["dc.relation.issn","0733-2459"],["dc.title","Prospective, randomized, sequential, crossover trial of large-volume vs. normal-volume leukapheresis procedures: Effects on subpopulations of CD34(+) cells"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","HLA"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Jarry, Hubertus"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:23:29Z"],["dc.date.available","2018-11-07T10:23:29Z"],["dc.date.issued","2017"],["dc.format.extent","345"],["dc.identifier.isi","000400973300016"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42465"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley"],["dc.publisher.place","Hoboken"],["dc.relation.issn","2059-2310"],["dc.relation.issn","2059-2302"],["dc.title","AN ALTERNATIVE SETUP FOR EXTRACORPOREAL PHOTOPHERESIS: 8-METHOXYPSORALEN AND UVA-TREATED LEUKOCYTES FROM ALLOGENEIC DONORS IMPROVE GRAFT VERSUS HOST DISEASE IN MICE"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","830"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Transfusion"],["dc.bibliographiccitation.lastpage","831"],["dc.bibliographiccitation.volume","43"],["dc.contributor.author","Koehler, M."],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Mayr, Wolfgang R."],["dc.contributor.author","Schwartz, DWM"],["dc.contributor.author","Heermann, K. H."],["dc.date.accessioned","2018-11-07T10:38:50Z"],["dc.date.available","2018-11-07T10:38:50Z"],["dc.date.issued","2003"],["dc.identifier.doi","10.1046/j.1537-2995.2003.00409.x"],["dc.identifier.isi","000183119000025"],["dc.identifier.pmid","12757539"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45903"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Blood Banks"],["dc.relation.issn","0041-1132"],["dc.title","Risk of transfusion-transmitted infections by NAT-negative blood"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","HLA"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:23:29Z"],["dc.date.available","2018-11-07T10:23:29Z"],["dc.date.issued","2017"],["dc.format.extent","362"],["dc.identifier.isi","000400973300051"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42466"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley"],["dc.publisher.place","Hoboken"],["dc.relation.issn","2059-2310"],["dc.relation.issn","2059-2302"],["dc.title","SCREENING FOR A BIOMARKER PANEL FOR PREDICTION OF GRAFT VERSUS HOST DISEASE IN HUMANS"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","465"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","472"],["dc.bibliographiccitation.volume","95"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Sorns, Marie-Sophie"],["dc.contributor.author","Welker, Pia"],["dc.contributor.author","Licha, Kai"],["dc.contributor.author","Wolff, Hendrik"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:18:30Z"],["dc.date.available","2018-11-07T10:18:30Z"],["dc.date.issued","2016"],["dc.description.abstract","Graft-versus-host disease (GvHD) is a severe immune reaction commonly occurring after hematopoietic stem cell transplantation. The outcome of patients who do not respond to the currently used immunosuppressive drugs is poor, thus there is an urgent need for the evaluation of new therapies. Heparin has a well-known anti-inflammatory effect and heparin analogues with a low anticoagulant effect are interesting candidates as new anti-inflammatory drugs. We explored the therapeutic potential of dendritic polyglycerol sulfates (dPGS), a novel class of heparin derivatives, on murine acute GvHD in vivo. The therapeutic effect of dPGS on murine GvHD was more intense after intravenous application compared to subcutaneous injection. An increased survival rate and improved clinical scores were observed in mice treated with 5 mg/kg once a week. In these animals, there was a reduction in the percentage of CD4(+) and CD8(+) T cells, which are the main effectors of GvHD. In addition, dPGS treatment decreased the number of tumor necrosis factor alpha (TNF alpha)-producing T cells. Increasing the dose of dPGS reversed the positive effect on survival as well as the clinical score, which indicates a small therapeutic range. Here, we report for the first time that dPGS have a significant immunosuppressive in vivo effect in a mouse model of severe acute GvHD. Therefore, we propose to study dPGS as promising candidates for the development of potential new drugs in the treatment of steroid-refractory GvHD patients first in larger animals and later in humans."],["dc.identifier.doi","10.1007/s00277-015-2565-y"],["dc.identifier.isi","000371605300013"],["dc.identifier.pmid","26634847"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41459"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-0584"],["dc.relation.issn","0939-5555"],["dc.title","Dendritic polyglycerol sulfate attenuates murine graft-versus-host disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1073"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Nucleosides, Nucleotides & Nucleic Acids"],["dc.bibliographiccitation.lastpage","1081"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Rau, Anne Lone"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias J."],["dc.date.accessioned","2020-12-10T18:15:14Z"],["dc.date.available","2020-12-10T18:15:14Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1080/15257770.2020.1755042"],["dc.identifier.eissn","1532-2335"],["dc.identifier.issn","1525-7770"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/74785"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Apoptosis induction by miR-19b inhibition: does it show therapeutic potential for leukemia?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e105896"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Kolb, Susanne"],["dc.contributor.author","Tejedor, Laura Salinas"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T09:36:27Z"],["dc.date.available","2018-11-07T09:36:27Z"],["dc.date.issued","2014"],["dc.description.abstract","Background: Graft-versus-host disease (GvHD) is a major challenge after hematopoietic stem cell transplantation but treatment options for patients are still limited. In many cases first-line treatment with glucocorticoids is not successful. Among second-line therapies the extracorporeal photopheresis (ECP) is frequently performed, due to induction of selective tolerance instead of general immunosuppression. However, for some patients with severe acute GvHD the leukapheresis step of the ECP procedure is physically exhausting and limits the number of ECP cycles. Methods: We hypothesized that leukocytes from healthy cell donors could be used as a replacement for ECP leukocytes gained from the GvHD patient. For this purpose we used a well established mouse model of acute GvHD. The ECP therapy was based on cells with the genetic background of the initial donor of the stem cell transplantation. As a precondition we developed a protocol representing conventional ECP in mice equivalent to clinical used ECP setup. Results: We could demonstrate that conventional, clinically derived ECP setup is able to alleviate acute GvHD. By using leukocytes obtained from healthy mice with the bone marrow donor's genetic background we could not observe a statistically significant therapeutic effect. Conclusions: Conventional human ECP setup is effective in the mouse model of severe acute GvHD. In addition we could not prove that ECP cells from healthy mice with bone marrow donor's genetic background are as effective as ECP cells derived from GvHD mice. Based on our findings, new questions arise for further studies, in which the cellular characteristics for ECP mediated immune tolerance are a matter of investigation."],["dc.description.sponsorship","Deutsche Jose Carreras Leukamie Stiftung e.V [DJCLS R 12/34]"],["dc.identifier.doi","10.1371/journal.pone.0105896"],["dc.identifier.isi","000341230600094"],["dc.identifier.pmid","25148404"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10790"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32622"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Modified Extracorporeal Photopheresis with Cells from a Healthy Donor for Acute Graft-versus-Host Disease in a Mouse Model"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","263"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Vox Sanguinis"],["dc.bibliographiccitation.lastpage","265"],["dc.bibliographiccitation.volume","86"],["dc.contributor.author","Schanz, J."],["dc.contributor.author","Wolf, C."],["dc.contributor.author","Koehler, M."],["dc.contributor.author","Maas, J. H."],["dc.contributor.author","Meyer, M."],["dc.contributor.author","Neumeyer, H."],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Riggert, Joachim"],["dc.date.accessioned","2018-11-07T10:49:32Z"],["dc.date.available","2018-11-07T10:49:32Z"],["dc.date.issued","2004"],["dc.identifier.doi","10.1111/j.0042-9007.2004.00486.x"],["dc.identifier.isi","000221402500007"],["dc.identifier.pmid","15144532"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48455"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing Ltd"],["dc.relation.issn","0042-9007"],["dc.title","Rhabdomyolysis in allogeneic peripheral blood stem cell donors"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","784"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Thrombosis and Haemostasis"],["dc.bibliographiccitation.lastpage","788"],["dc.bibliographiccitation.volume","84"],["dc.contributor.author","Humpe, Andreas"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Nubling, C. M."],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Unger, G."],["dc.contributor.author","Wolf, C."],["dc.contributor.author","Heermann, K. H."],["dc.contributor.author","Kohler, M."],["dc.date.accessioned","2018-11-07T08:54:09Z"],["dc.date.available","2018-11-07T08:54:09Z"],["dc.date.issued","2000"],["dc.description.abstract","In 1994, quarantine fresh-frozen plasma (Q-FFP) was introduced in Germany in order to reduce the risk of HIV and HCV transmission In 1998, an acute HCV infection of a patient was reported to us. The look-back revealed that this patient had received two Q-FFP from a donor who had seroconverted for HCV in the meantime. Recipients of further plasma donations from this donor were identified. Back-up specimens of these donations were investigated in several laboratories. A total of 25 additional HCV-PCR positive plasma units had been transfused to 12 further patients. HCV infections were diagnosed in seven of these recipients, three patients had already been deceased. One of the remaining two recipients was already HCV positive prior to transfusion, in the other patient, no HCV infection was detectable. This patient had received three units of an \"early\" plasma donation, which was tested negative by PCR in one laboratory, but positive in the other. The subsequent, clinically infectious donation had the same discrepant PCR results. Thus, eight cases of HCV transmission were revealed and classified as \"certain\" with regard to causality, also due to an identical HCV genotype, i.e. 3e. Some of these infections would have been prevented by application of a different anti-HCV assay. The assay used in the respective plasmapheresis station was in-sensitive in this individual case for more than 400 days after the first PCR positive donation. This caused the release of the above mentioned infectious units. Upon re-testing the backups, three of four other anti-HCV assays revealed a positive result already 104 days after the first PCR-positive donation. The donor had increased ALAT levels (> 23 IU/L) at nine of 28 donations, two of these were higher than 2.5 times the upper normal limit, and two were higher than 68 IU/L, which is the cut-off value for male blood donors in Germany. The results of these (look-back) studies arouse several queries, i.e, differences in the diagnostic sensitivity between current anti-HCV and PCR tests, the accuracy of risk-estimates (especially when based on hemovigilance studies for Q-FFP), the value of ALAT testing, and currently practised release algorithms for Q-FFP."],["dc.identifier.isi","000165403900010"],["dc.identifier.pmid","11127856"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22607"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","F K Schattauer Verlag Gmbh"],["dc.relation.issn","0340-6245"],["dc.title","Hepatitis C virus transmission through quarantine fresh-frozen plasma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]